论文部分内容阅读
目的：研究使用美托洛尔联合曲美他嗪治疗冠心病心力衰竭临床效果。方法：选取我院收治的92例冠心病心力衰竭患者，随机分为观察组和对照组，每组46例，对照组给予常规治疗，观察组在对照组的基础上进行美托洛尔联合曲美他嗪进行治疗。比较两组患者的治疗效果及心血管功能改善情况。结果：观察组患者SBP、LVEF明显高于对照组，DBP、HR、LVEDD、LVESD等明显低于对照组，差异有统计学意义（P＜0.05）；观察组总有效率97.83％，对照组总有效率84.78％，观察组显著高于对照组，差异有统计学意义（P＜0.05）。结论：联用美托洛尔和曲美他嗪治疗冠心病心力衰竭，相对于常规疗法，效果更为显著，值得临床推广。“,”Objective: To study the use of metoprolol combined with trimetazidine QuMei therapeutic effect for the treatment of coronary heart disease and heart failure. Methods: 92 cases of coronary heart disease and heart failure patients in our hospital, were randomly divided into observation group and control group, 46 cases in each group, the control group was given routine treatment, the observation group in the control group were Sibutramine metoprolol combined with trimetazidine comparison of treatment. The treatment effect and cardiovascular function in the patients of the two groups improved. Results: the patients in the observation group SBP, LVEF was significantly higher than the control group, DBP, HR, LVEDD, LVESD signiifcantly lower than the control group, the difference was statistically signiifcant (P < 0.05); the observation group the total efifciency of 97.83%, the total efifciency of the control group 84.78%, the observation group was signiifcantly higher than the control group, the difference was statistically significant (P < 0.05). Conclusion: the combined use of metoprolol and trimetazidine treatment of coronary heart disease and heart failure QuMei, compared with the conventional therapy, the effect is more As signiifcant, it is worthy of clinical promotion.